Biotechnology

Axonia Medical Announces Exclusive Partnerships with Leading Biotechnology and Microbiology Equipment Manufacturers

December 5, 2024 12:30 PM

SINGAPORE, SINGAPORE / ACCESSWIRE / December 5, 2024 / Axonia Medical is a leading provider of lab equipment. The company is excited to announce its exclusive partnerships. These partnerships are with well-known manufacturers in the biotechnology and microbiology fields. Axonia Medical collaborates with major companies. These include Abbott, Beckman Coulter, Sysmex, Roche, Bio-Rad, Mindray, Siemens, Horiba, and Perkin Elmer. This helps labs...

Read more

TeselaGen Launches Its Next-Gen Electronic Lab Notebook and Enhanced Interface to Accelerate Biotech Research

December 5, 2024 10:00 AM

TeselaGen Biotechnology, a leader in advanced software solutions for the biotechnology industry, has announced the release of its new Electronic Lab Notebook (ELN) alongside a unified user interface designed to improve user experience. These advancements are set to streamline laboratory workflows, improve data management, and foster collaboration among scientists in the biotech sector. TeselaGen's Electronic Lab Notebook (ELN) The TeselaGen ELN...

Read more

Xenetic Biosciences, Inc. Enters into Clinical Trial Services Agreement with PeriNess Ltd. to Accelerate Development of DNase I Oncology Program

December 5, 2024 8:45 AM

Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing hard to treat cancers, today announced it has entered into a Clinical Trial Services Agreement (the "Agreement") with the Israel-based biotechnology company PeriNess Ltd. ("PeriNess") to advance the Company's development program for its systemic DNase I candidate in combination...

Read more

Senior Pharma and Biotech Leaders to Gather the Weekend Immediately Prior to JP Morgan Healthcare Conference for 2 Day Networking Forum, San Francisco CEO, Hosted by Longwood Healthcare Leaders

December 5, 2024 7:00 AM

BOSTON, MA / ACCESSWIRE / December 4, 2024 / Longwood Healthcare Leaders will convene top biopharmaceutical leaders for two days of discussion, January 11-12, 2025, the weekend immediately prior to the 43rd Annual JP Morgan Health Care Conference. San Francisco CEO is held at the Four Seasons Hotel San Francisco, 757 Market Street, in downtown San Francisco, and features approximately 150 speakers across government, pharma, biotech, academia,...

Read more

Indica Labs Joins the AWS Partner Network

December 4, 2024 8:00 AM

Indica Labs, the global leader in AI-powered digital pathology software and services, announced today that they have joined the Amazon Web Services (AWS) Partner Network (APN). The APN is a global community of AWS Partners that leverage programs, expertise, and resources to build, market, and co-sell customer offerings. With the successful completion of the foundational technical review of HALO®, HALO AI, HALO Link, and HALO AP®, these platforms...

Read more

Alligator Bioscience Publishes Financial Calendar for 2025

December 4, 2024 3:00 AM

LUND, SE / ACCESSWIRE / December 04, 2024 / Alligator Bioscience (STO:ATORX) Lund, Sweden - Alligator Bioscience (Nasdaq Stockholm: ATORX), hereby publishes its financial calendar for 2025: Extraordinary General Meeting 13 January 2025 Deadline for Alligator Bioscience's shareholders to submit resolutions to be considered by the Annual General Meeting 31 January 2025 Year-end report 2024 22 January 2025 Annual report 2024 March 2025 Interim...

Read more

Alligator Announces First Patient Dosed in Shanghai Henlius Biotech, Inc. Phase 3 Clinical Trial

December 4, 2024 2:50 AM

LUND, SE / ACCESSWIRE / December 04, 2024 / Alligator Bioscience (STO:ATORX) Lund, Sweden, November 27, 2024 - Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the Company was notified that the first patient has been dosed in a Phase 3 clinical trial with Shanghai Henlius Biotech, Inc. Alligator out-licensed HLX22/AC101 to AbClon, Inc. in October 2016. Abclon, Inc. subsequently sub-licensed AC101 for clinical development by...

Read more

BioInvent Appoints Ashley Robinson as SVP Strategy & Finance to Lead US Expansion

December 3, 2024 2:30 AM

LUND, SWEDEN and BOSTON, MA / ACCESSWIRE / December 3, 2024 /BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces the appointment of Ashley Robinson as SVP Strategy & Finance, effective as of today. In this role, Mr. Robinson will spearhead efforts to strengthen BioInvent's...

Read more

Exercise price determined for the exercise of warrants series TO 9 in Alligator Bioscience AB

December 2, 2024 11:35 AM

LUND, SE / ACCESSWIRE / December 2, 2024 / Alligator Bioscience (STO:ATORX) Alligator Bioscience AB ("Alligator" or the "Company") hereby announces that the exercise price for warrants series TO 9 (the "warrants") has been determined to SEK 0.55. The exercise period for the warrants commences on 4 December 2024 and runs up to and including 18 December 2024. The last day for trading in the warrants is 13 December 2024. Alligator carried out a...

Read more

IGC Pharma Advances IGC-AD1 as a Potential Alzheimer's Therapy Addressing Cognitive Impairment and Underlying Disease Pathology

December 2, 2024 8:30 AM

IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") announced today an expansion of its clinical research program for IGC-AD1, an investigational treatment for Alzheimer's disease. Building on Phase 2 interim results demonstrating reductions in agitation and cognitive improvement, the Company is initiating new trials to evaluate IGC-AD1's potential as a disease-modifying therapy. The expanded research will explore how IGC-AD1's...

Read more

Alligator Sharpens Focus on Mitazalimab and Announces Cost Reduction Program to Maximize Long-Term Value Creation

December 2, 2024 3:00 AM

Sharpening focus on preparing mitazalimab for Phase 3 and continuing partnering discussions Planned reduction of workforce, mainly within Discovery and Non-Clinical unit Expected annual cash savings of at least SEK 65 million Will continue to conduct limited research activities, primarily related to mitazalimab LUND, SE / ACCESSWIRE / December 02, 2024 / Alligator Bioscience AB ("Alligator" or the "Company") announced today that it is sharpening...

Read more

Notice of Extraordinary General Meeting in Alligator Bioscience AB

December 2, 2024 3:00 AM

LUND, SE / ACCESSWIRE / December 02, 2024 / Alligator Bioscience (STO:ATORX) The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. The shareholders of Alligator Bioscience AB, Reg. No. 556597-8201, are invited to the extraordinary general meeting to be held on Monday 13 January 2025 at 11.30 CET, at Medicon Village, conference room Bengt,...

Read more

Alligator Bioscience Carries out a Rights Issue of Units of Approximately SEK 280 Million and Raises Bridge Loans

December 2, 2024 3:00 AM

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE. LUND, SE / ACCESSWIRE / December 02, 2024 / Alligator Bioscience (STO:ATORX) The Board of...

Read more

Biovica Signs Agreement with American Health Giant

December 2, 2024 2:20 AM

UPPSALA, SE / ACCESSWIRE / December 02, 2024 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B) (FRA:9II) Biovica, active in blood-based cancer monitoring, today announces that the company has entered into a commercial agreement (client bill) with one of the largest health insurance companies in the US, with revenues exceeding 100 billion USD. The company is both a health insurance and a health care service provider serving over 10 million...

Read more

enVVeno Medical Highlights Successful 2024 VEITH Symposium with Launch of Recap Website

November 27, 2024 8:30 AM

Interviews with participating patients from the VenoValve® U.S. Pivotal Trial Webcast replay from with the presenting Primary Investigators Presentation with data from the VenoValve U.S. Pivotal Trial Access the Recap Website Here! IRVINE, CA / ACCESSWIRE / November 27, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced the...

Read more

AI Maverick: The Next Evolution of Sales Automation Unveiled in Exclusive Podcast

November 27, 2024 7:30 AM

Bionoid Pharma (OTC PINK:BINP) unveils AI Maverick's game-changing sales automation in the latest episode of the BizUnLearned Podcast. Discover how this revolutionary platform is set to transform the traditional sales process, one touchpoint at a time. "Imagine a world where technology doesn't just assist your sales teams but replaces repetitive tasks entirely," highlighted in the podcast. "AI Maverick learns, adapts, and delivers results,...

Read more

FluoGuide A/S Publishes Interim Report for the Period January – September 2024

November 27, 2024 1:20 AM

KØBENHAVN, DK / ACCESSWIRE / November 27, 2024 / FluoGuide A/S (STO:FLUO) Copenhagen, Denmark, 27 November 2024 - Fluoguide A/S ("FluoGuide" or the "Company") today releases its results for the period 1 January 2024 - 30 September 2024. The Q3 report is available as attached document to this press release and on FluoGuide's website. In the third quarter, preparations for the FG001 phase II head and neck trial application (CT-005) were made,...

Read more

Join Enlivex Therapeutics' Exclusive Live Investor Webinar and Q&A Session on December 3

November 26, 2024 10:15 AM

Enlivex Therapeutics Ltd. (Nasdaq:ENLV)(the "Company"), a clinical-stage macrophage reprogramming immunotherapy company, is pleased to invite investors to a webinar on December 3, 2024, at 11:00 a.m. ET. The exclusive event, hosted by RedChip Companies, will feature Enlivex Therapeutics Chief Executive Officer Oren Hershkovitz who will share insight into the Company's lead product, Allocetra™, insight into the clinical status, and 2025 planned...

Read more

The End of SDRs? AI Maverick Sales Automation, One Touchpoint at a Time

November 26, 2024 7:30 AM

NEW YORK CITY, NY / ACCESSWIRE / November 26, 2024 / Bionoid Pharma, Inc. ("BINP") (OTC PINK:BINP) - Bionoid Pharma, Inc. ("Bionoid") ("BINP") (OTC Pink:BINP), the new owner of the AI Maverick platform, is disrupting the world of sales and communication industry with cutting-edge AI automation technology set to transform how businesses engage, nurture, and convert leads. While most traditional technology solutions focus on supporting overwhelmed...

Read more

New DiviTum(R) TKa data to be Presented at SABCS that Significantly Broaden the Addressable Market

November 26, 2024 2:20 AM

UPPSALA, SE / ACCESSWIRE / November 26, 2024 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B) (FRA:9II) Biovica, active in cancer monitoring, announces that seven abstracts based on studies using the blood test DiviTum TKa will be presented at the world's largest breast cancer meeting, San Antonio Breast Cancer Symposium (SABCS) on December 10-13, 2024. Two of the abstracts validates DiviTum TKa in the adjuvant setting (early breast cancer),...

Read more